Welcome Aboard mate.
I am just speculating here, but the fact that was were mixing with Lipitor. I wouldn't be surprised if we are already in light talks with Pzifer, especially considering that AZ already picked up Dogma. Pzifer will defiantly be on the hunt to protect there market control of Chol reducing drugs.
Heads up, this is going to be a fun one and might happen sooner than we think.
Dogma was picked up pre clinical trials. From Dogma TO Article "There are currently no oral PCSK9 inhibitors available to patients or in clinical development."
We must be very close behind them.
AZ is starting 2021 Clinical development what ever that means..
Not to mention that Pzifer stopped there 2015 Oral trials.
Welcome Aboard mate.I am just speculating here, but the fact...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.010(12.5%) |
Mkt cap ! $12.55M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 6.6¢ | $170.2K | 2.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 141927 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.1¢ |
Change
-0.010 ( 11.3 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.1¢ | 6.6¢ | 865359 | ||
| Last updated 15.36pm 09/05/2024 ? | |||||
| NYR (ASX) Chart |